Professor Daniel C. Baumgart, MD PhD MBA FRCP (Lon) FACP AGAF


Department of Gastroenterology and Hepatology
Charité Medical Center - Virchow Hospital
Medical School of the Humboldt-University of Berlin
Augustenburger Platz 1
13353 Berlin

daniel.baumgart@charite.de

Deutsch

Biosketch

Daniel C. Baumgart, MD PhD MBA FACP FRCP (Lon) AGAF went to medical school in Berlin, Basle (Switzerland) and Würzburg (Bavaria). He received his training in internal medicine, gastroenterology, hepatology and immunology at the Charité and as a German Academic Exchange Service (DAAD) and German Research Council (DFG) scholar at the University of Pennsylvania, Philadelphia, PA, USA, Georgetown University, Washington, DC, USA, Lombardi Cancer Center, National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) Bethdesda, MD, USA, Inova Fairfax Hospital Fairfax, VA, USA, Virginia Hospital Center, Arlington, VA, USA as well as US Public Health Service und Veterans Affairs Medical Center in Washington, DC, USA. Dr. Baumgart holds an unrestricted license to practice medicine and surgery in the US, Canada and Germany. Prior to his current appointment as Professor of Gastroenterology and Hepatology and Director, Division of Gastroenterology, AHS Zone Head and Director of the Inflammatory Bowel Disease Program at the University of Alberta in Edmonton, Canada he served as Professor of Medicine at Charité Medical School of the Humboldt-University of Berlin, Deputy Chief of the Department of Gastroenterology and Hepatology and Director the Inflammatory Bowel Disease Center at Charité's Virchow Campus and elected fellow at the Berlin Institute of Health (BIH) endowed by the StiftungCharité foundation. He is also Visiting Professor at Peking University, Beijing China and was Visiting Professor at Yale University, New Haven, CT and Harvard University, Boston, MA, USA. Dr. Baumgart is actively involved in the development and evaluation of novel diagnostic and therapeutic concepts for Crohn’s disease and ulcerative colitis including new modalities of optical detection to visualize inflammation, mucosal damage and epithelial restitution and image guided intervention. He has been principal investigator in some 200 multinational clinical trials. A trailblazer of digitization he has a strong interest in evidence based medicine and the application of computers and communication technology in education, research, systems medicine with integration of clinical and scientific data, mathematical modeling of diseases and big data all ultimately aiming to provide precision medicine at the point of care. His basic science laboratory is focused on the investigation of dendritic cells in innate and adaptive immunity, especially microbial recognition and human microbiome. His research has been supported by major national and international funding bodies. Dr. Baumgart has been serving on the editorial boards of leading medical and scientific journals including The Lancet, Gut and Inflammatory Bowel Diseases for more than a decade as well as the secretary of the World Gastroenterology Organization IBD task force, elected member of the Cochrane IBD special interest group, elected board member of the IBD task force of the German Society for Gastroenterology (DGVS) and sits on various other national and international expert and guideline panels. A BMW Herbert Quandt Foundation responsible leadership alumnus and passionate educator, Dr. Baumgart developed an innovative integrated clinical and research training curriculum for academic physicians, that received numerous awards including the VolkswagenStiftung foundation's off the beaten track award for its extraordinary design and visionary impetus to academia and has been approved by the German Research Council (DFG), Federal Ministry for Education and Research (BMBF), the German Council of Science and Humanities (WR) and adopted by German medical schools nationwide. In 2013 Dr. Baumgart was appointed fellow, American College of Physicians (FACP), Philadelphia; in 2014 fellow, American Gastroenterological Association (AGAF), Bethesda; and in 2017 Fellow of the Royal College of Physicians (FRCP), London, UK.

Major Clinical Interests

Inflammatory Bowel Disease (IBD) (Crohn’s Disease, Ulcerative Colitis, Fistulas, Pouchitis, Regional Enteritis, Ileitis, Ileocolitis), Celiac Disease (Non-Tropical Sprue, Gluten Enteropathy, Celiac Sprue), autoimmune enteropathy, enteral and parenteral nutrition, short bowel syndrome, immune deficiency disorders, immune defects, infections and other inflammatory disorders

Internet Based Patient Information and Support Groups

Ongoing Clinical Trials in Inflammatory Bowel Disease (NIH Database)
CCFA: Crohn's & Colitis Foundation of America
European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA)
Celiac Sprue Association USA
Coeliac UK (Charity Supporting People with Gluten Intolerance)

Books

eBooks
Inflammatory Bowel Disease

Crohn's Disease
Ulcerative Colitis
Celiac Sprue

Information for Students (Teaching)

Recommended Books
Educational Matererials on the Open Source Course Management System Moodle
Dr. Baumgart's Mobile Medical Educator
Medical and scientific podcasts
Application of US American medical teaching and training methodology (e.g., problem oriented learning)

Major Research Interests

Basic Science Research Laboratory

Intestinal barrier, interaction of atypical (epithelial cells) and professional (dendritic cells) antigen presenting cells with microbial antigens of the microbiome, innate and adaptive immunity in infection and inflammation

Optical Detection und Imaging Guided Intervention

Lasermicroskopy, confocal microscopy, endocytoscopy, endoscopy, chromendoscopy, ultrasound (sonography), intestinal ultrasound, 3D and contract enhanced imaging and intervention, elastography

Personalized medicine in inflammatopry bowel disease

Immunomodulators, immunosuppressants, monoclonal antibodies, biologics, prebiotics, probiotics, antibiotics, adhesion molecule blockers, cell based immunotherapy, monoclonal antibodies against pro-inflammatory cytokines, fusion proteins, inhibitors of costimulatory molecules, prevention and management of malignant complications

Systems Medicine

Integration of clinical and scientific data, mathematical modeling of diseases, big data

Professional Membership

American Medical Association (AMA)
American Gastroenterological Association (AGA)
AGA Institute Council: Immunology, Microbiology & Inflammatory Bowel Disease & Gastrointestinal Oncology
American Society for Gastrointestinal Endoscopy (ASGE)
German Society for Gastroenterology and Metabolic Diseases (DGVS)
Gesellschaft für Gastroenterologie und Hepatologie in Berlin und Brandenburg e.V.
German Inflammatory Disease Network and Task Force (DACED)
German Inflammatory Bowel Disease Study Group Board (GISG)
European Crohn's and Colitis Organization (ECCO)
New Traditions Network (US Embassy and US Department of State)
Universities of the Future Project
Berlin International Studies Network (BISS)
German Academic Exchange Service (DAAD) Alumni Organization
Transatlantic Forum (Herbert Quandt Foundation)
World Young Leaders Forum
German University Professor Association (DHV)

Peer Review

Editorial Boards

Editorial Consultant at The Lancet
Member, Editorial Board: Gut
Section Editor: Inflammatory Bowel Diseases
Member, Editorial Board: European Gastroenterology & Hepatology Review
Member, Editorial Board: World Journal of Gastroenterology
Member, Editorial Board: The International Journal of Probiotics and Prebiotics
Member, Editorial Advisory Board: Recent Patents on Anti-Infective Drug Discovery
Member, Editorial Advisory Board: Recent Patents on Anti-Cancer Drug Discovery
Guest Editor Special Series on Inflammatory Bowel Disease: World Journal of Gastroenterology 2008
Guest Editor Special Series on Celiac Disease: World Journal of Gastroenterology 2009

Ad hoc reviewer for

Journals

Annals of the Rheumatic Diseases
British Journal of Surgery
Biomed Central
Clinical Gastroenterology and Hepatology
Clinical Pharmacology and Therapeutics
Deutsches Ärzteblatt (German Medical Weekly)
Digestive Surgery
Diseases of the Colon and Rectum
Drugs of Today
Endoscopy
European Journal of Pediatrics
European Journal of Gastroenterology and Hepatology
Expert Review of Gastroenterology and Hepatology
Expert Review of Molecular Diagnostics
Experimental Pharmacology
Future Drugs
Frontiers in Bioscience
Gastroenterology
Gastrointestinal Endoscopy
Gut
Human Immunology
Inflammatory Bowel Diseases
Immunobiology
Inflammopharmacology
JAMA (Journal of the American Medical Association)
Journal of Crohn’s and Colitis
Molecular Nutrition and Food Research
New England Journal of Medicine
Nutrition
Pediatrics
Pharmacogenomics
Recent Patents on Anti-Infective Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery
Scandinavian Journal of Infectious Diseases
The American Journal of Clinical Dermatology
The American Journal of Gastroenterology
The American Journal of Physiology
The Journal of Immunology
The Journal of Clinical Investigation
The Lancet
The Lancet Infectious Diseases
The New England Journal of Medicine
Word Journal of Gastroenterology
Zeitschrift für Gastroenterologie

Institutions, Scientific Foundations and Grant und Funding Agencies

German Research Council (DFG)
Cochrane Library Special Interest Group Inflammatory Bowel Disease

The Wellcome Trust, London, UK
The French National Research Agency / L'Agence nationale de la recherche (ANR), Paris, France
Health Research Board (An Bord Taighde Sláinte), Dublin, Ireland
AGA Institute Council: Immunology, Microbiology & Inflammatory Bowel Disease & Gastrointestinal Oncology, Bethesda, MD, USA
Biomedical Research Council and Ministry of Health's National Medical Research Council of Singapore
The Eli and Edythe L. Broad Foundation for IBD Research, Los Angeles, CA, USA
ZonMW (The Netherland Organisation für Health Research and Development), Den Haag, The Netherlands
FWF - Austrian Science Fund, Vienna, Austria
Israel Science Foundation (ISF), Jerusalem, Israel
United States-Israel Binational Science Foundation (BSF), Jerusalem, Israel
Academy of Finland (Suomen Akatemia, Terveyden tutkimuksen yksikkö), Helsiniki, Finland
Uni-Med Science Publishers, Boston, MA, USA
Drug Safety Institute, Miami, FL, USA

Publications

1             Baumgart DC, Gerl H, Dorner T. Complete heart block caused by primary Sjogren's syndrome and hypopituitarism. Ann Rheum Dis 1998;57:635.
2             Baumgart DC, McVay LD, Carding SR. Mechanisms of immune cell-mediated tissue injury in inflammatory bowel disease (Review). Int J Mol Med 1998;1:315-32.
3             Baumgart DC, Olivier WA, Reya T, Peritt D, Rombeau JL, Carding SR. Mechanisms of intestinal epithelial cell injury and colitis in interleukin 2 (IL2)-deficient mice. Cell Immunol 1998;187:52-66.
4             Baumgart DC, Ventz M, Wermke W. [18-year-old patient with hypercalcemia, hypophosphatemia, nephrocalcinosis and normal iPTH values. Primary hyperparathyroidism]. Internist (Berl) 1998;39:403-8.
5             Contractor NV, Bassiri H, Reya T, Park AY, Baumgart DC, Wasik MA, Emerson SG, Carding SR. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol 1998;160:385-94.
6             Macartney KK, Baumgart DC, Carding SR, Brubaker JO, Offit PA. Primary murine small intestinal epithelial cells, maintained in long-term culture, are susceptible to rotavirus infection. J Virol 2000;74:5597-603.
7             Telega GW, Baumgart DC, Carding SR. Uptake and presentation of antigen to T cells by primary colonic epithelial cells in normal and diseased states. Gastroenterology 2000;119:1548-59.
8             Baumgart DC, Dignass AU. [Intestinal gene regulation by commensal microflora. Remote control from within?]. Z Gastroenterol 2001;39:815-7.
9             Baumgart DC, Dignass AU. Intestinal barrier function. Curr Opin Clin Nutr Metab Care 2002;5:685-94.
10           Baumgart DC, Dignass AU. Shingles following infliximab infusion. Ann Rheum Dis 2002;61:661.
11           Baumgart DC, Dignass AU. [Mucosal dendritic cells: reaching out for the unknown (antigen)]. Z Gastroenterol 2002;40:375-7.
12           Baumgart DC, Dignass AU. [Tacrolimus (FK506) in refractory ulcerative colitis: an alternative to proctocolectomy?]. Z Gastroenterol 2003;41:478-9.
13           Baumgart DC, Gerl H. Photo quiz. Obesity and daytime sleepiness. Prader-Willi syndrome. Am Fam Physician 2003;68:151-2.
14           Baumgart DC, Wiedenmann B, Dignass AU. [Biologic therapy of inflammatory bowel disease]. Z Gastroenterol 2003;41:1017-32.
15           Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003;17:1273-81.
16           Baumgart DC, Dignass AU. Current biological therapies for inflammatory bowel disease. Curr Pharm Des 2004;10:4127-47.
17           Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis. Inflamm Bowel Dis 2004;10:421-4.
18           Cruickshank SM, McVay LD, Baumgart DC, Felsburg PJ, Carding SR. Colonic epithelial cell mediated suppression of CD4 T cell activation. Gut 2004;53:678-84.
19           Dignass AU, Baumgart DC, Sturm A. Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms. Aliment Pharmacol Ther 2004;20 Suppl 4:9-17.
20           Baumgart DC. Personal digital assistants in health care: experienced clinicians in the palm of your hand? Lancet 2005;366:1210-22.
21           Baumgart DC, Metzke D, Schmitz J, Scheffold A, Sturm A, Wiedenmann B, Dignass AU. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut 2005;54:228-36.
22           Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 2005;54:1822-3.
23           Baumgart DC, Veltzke-Schlieker W, Wiedenmann B, Hintze RE. Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointest Endosc 2005;61:473-5.
24           Baumgart DC, Vierziger K, Sturm A, Wiedenmann B, Dignass AU. Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Scand J Gastroenterol 2005;40:958-64.
25           Baumgart DCV-S, W.; Wiedenmann, B. Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointest Endosc 2005;62:648.
26           Baumgart DCV-S, W.; Wiedenmann, B.; Hintze, R.E. Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointest Endosc 2005;61:473-5.
27           Dignass AU, Baumgart DC. New treatment strategies in Crohn's disease: Step-up versus top-down. Verdauungskrankheiten 2005;23:186-91.
28           Sturm A, Baumgart DC, d'Heureuse JH, Hotz A, Wiedenmann B, Dignass AU. CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine 2005;29:42-8.
29           Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazale T, Raupach B, Eckert J, Schumann RR, Enders C, Sonnenborn U, Wiedenmann B, Dignass AU. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun 2005;73:1452-65.
30           Andresen VB, D.C. Role of probiotics in the treatment of irritable bowel syndrome: potential mechanisms and current clinical evidence. International Journal of Probiotics & Prebiotics 2006;1:11-8.
31           Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol 2006;101:1048-56.
32           Baumgart DCT, B.T., Dignass, A. Therapie chronisch-entzündlicher Darmerkrankungen mit Biologika und Immunmodulatoren. D Bay Int 2006;26:144-8.
33           Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B, Sonnenborn U, Eckert J, Schumann RR, Wiedenmann B, Dignass AU, Sturm A. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun 2006;74:4075-82.
34           Tanczos BT, Baumgart DC. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?]. Z Gastroenterol 2006;44:609-10.
35           Baumgart DC. Recognition and appropriate management of dysplasia-associated lesions or masses in inflammatory bowel disease--experience does matter. Gastrointest Endosc 2007;66:530-2.
36           Baumgart DC, Buning C, Geerdts L, Schmidt HH, Genschel J, Fiedler T, Gentz E, Molnar T, Nagy F, Lonovics J, Lochs H, Wiedenmann B, Nickel R, Witt H, Dignass A. The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion 2007;76:196-202.
37           Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40.
38           Baumgart DC, Fischer A. Virchow's node. Lancet 2007;370:1568.
39           Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57.
40           Buning C, Durmus T, Molnar T, de Jong DJ, Drenth JP, Fiedler T, Gentz E, Todorov T, Haas V, Buhner S, Sturm A, Baumgart DC, Nagy F, Lonovics J, Landt O, Kage A, Buning H, Nickel R, Buttner J, Lochs H, Schmidt HH, Witt H. A study in three European IBD cohorts confirms that the ATG16L1 c.898A>G (p.Thr300Ala) variant is a susceptibility factor for Crohn's disease. J Crohns Colitis 2007;1:70-6.
41           Buning C, Schmidt HH, Molnar T, De Jong DJ, Fiedler T, Buhner S, Sturm A, Baumgart DC, Nagy F, Lonovics J, Drenth JP, Landt O, Nickel R, Buttner J, Lochs H, Witt H. Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis. Aliment Pharmacol Ther 2007;26:1025-33.
42           Schott E, Paul F, Wuerfel JT, Zipp F, Rudolph B, Wiedenmann B, Baumgart DC. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. World J Gastroenterol 2007;13:3638-40.
43           Weylandt KH, Kang JX, Wiedenmann B, Baumgart DC. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis 2007;13:797-9.
44           Baumgart DC. What's new in inflammatory bowel disease in 2008? World J Gastroenterol 2008;14:329-30.
45           Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 2008:CD007216.
46           Berndt U, Philipsen L, Bartsch S, Wiedenmann B, Baumgart DC, Hammerle M, Sturm A. Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancer. Cancer Res 2008;68:880-8.
47           Buning C, Schmidt HH, Molnar T, Drenth JP, Fiedler T, Gentz E, Todorov T, Baumgart DC, Sturm A, Nagy F, Lonovics J, de Jong DJ, Landt O, Kage A, Nickel R, Buttner J, Lochs H, Witt H. No association of the CARD8 (TUCAN) c.30T>A (p.C10X) variant with Crohn's disease: a study in 3 independent European cohorts. Inflamm Bowel Dis 2008;14:332-7.
48           Niesner U, Albrecht I, Janke M, Doebis C, Loddenkemper C, Lexberg MH, Eulenburg K, Kreher S, Koeck J, Baumgrass R, Bonhagen K, Kamradt T, Enghard P, Humrich JY, Rutz S, Schulze-Topphoff U, Aktas O, Bartfeld S, Radbruch H, Hegazy AN, Lohning M, Baumgart DC, Duchmann R, Rudwaleit M, Haupl T, Gitelman I, Krenn V, Gruen J, Sieper J, Zeitz M, Wiedenmann B, Zipp F, Hamann A, Janitz M, Scheffold A, Burmester GR, Chang HD, Radbruch A. Autoregulation of Th1-mediated inflammation by twist1. J Exp Med 2008;205:1889-901.
49           Paul F, Pfueller CF, Wuerfel JT, Egerer K, Tanczos B, Baumgart DC, Zipp F. Celiac antibodies in the diagnostic workup of white matter lesions. Neurology 2008;71:223-5.
50           Baumgart DC. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int 2009;106:123-33.
51           Baumgart DC, Lowder JN, Targan SR, Sandborn WJ, Frankel MB. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol 2009;104:868-76.
52           Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, Lehnardt S, Dorffel Y, Sturm A, Scheffold A, Schmitz J, Radbruch A. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin Exp Immunol 2009;157:423-36.
53           Habbel P, Weylandt KH, Lichopoj K, Nowak J, Purschke M, Wang JD, He CW, Baumgart DC, Kang JX. Docosahexaenoic acid suppresses arachidonic acid-induced proliferation of LS-174T human colon carcinoma cells. World J Gastroenterol 2009;15:1079-84.
54           Hasper D, Schefold JC, Baumgart DC. Management of severe abdominal infections. Recent Pat Antiinfect Drug Discov 2009;4:57-65.
55           Pohl H, Rosch T, Tanczos BT, Rudolph B, Schluns K, Baumgart DC. Endocytoscopy for the detection of microstructural features in adult patients with celiac sprue: a prospective, blinded endocytoscopy-conventional histology correlation study. Gastrointest Endosc 2009;70:933-41.
56           Thomas S, Przesdzing I, Metzke D, Schmitz J, Radbruch A, Baumgart DC. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clin Exp Immunol 2009;156:78-87.
57           Baumgart DC. How many lives does an ulcerative colitis patient have? Lancet 2010;376:928.
58           Baumgart DC. CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis. Curr Opin Investig Drugs 2010;11:571-6.
59           Baumgart DC. Veto on vedolizumab (MLN0002) for Crohn's disease. Inflamm Bowel Dis 2010;16:537-8.
60           Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2010;16:620-9.
61           Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S. Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther 2010;31:1286-95.
62           Muller T, Baumgart DC. [Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: the more the better?]. Z Gastroenterol 2010;48:569-70.
63           Sandborn WJ, Colombel JF, Frankel M, Hommes D, Lowder JN, Mayer L, Plevy S, Stokkers P, Travis S, Van Assche G, Baumgart DC, Targan SR. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 2010;59:1485-92.
64           Schirbel A, Reichert A, Roll S, Baumgart DC, Buning C, Wittig B, Wiedenmann B, Dignass A, Sturm A. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol 2010;16:3168-77.
65           Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkuhn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E, European Cs, Colitis O. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
66           Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Soderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J, European Cs, Colitis O. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010;4:63-101.
67           Baumgart DC. Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when? Dig Dis 2011;29 Suppl 1:32-5.
68           Baumgart DC. Smartphones in clinical practice, medical education, and research. Arch Intern Med 2011;171:1294-6.
69           Baumgart DC. Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis. Evid Based Med 2011;16:71-2.
70           Baumgart DC. Foreword. European Gastroenterology and Hepatology Review 2011;7:152-3.
71           Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D'Haens G, Dotan I, Goh KL, Hibi T, Kozarek RA, Quigley EM, Reinisch W, Sands BE, Sollano JD, Steinhart AH, Steinwurz F, Vatn MH, Yamamoto-Furusho JK. IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis 2011;17:639-44.
72           Baumgart DC, Grittner U, Steingraber A, Azzaro M, Philipp S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis 2011;17:2512-20.
73           Baumgart DC, Metzke D, Guckelberger O, Pascher A, Grotzinger C, Przesdzing I, Dorffel Y, Schmitz J, Thomas S. Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis. Clin Exp Immunol 2011;166:46-54.
74           Eckardt AJ, Baumgart DC. Viral gastroenteritis in adults. Recent Pat Antiinfect Drug Discov 2011;6:54-63.
75           German IBDSG. [Adherence to the H1N1 vaccination recommendation in patients with Crohn's disease or ulcerative colitis]. Dtsch Med Wochenschr 2011;136:939-43.
76           Thomas S, Metzke D, Schmitz J, Dorffel Y, Baumgart DC. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2011;301:G1083-92.
77           Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366:601-9.
78           Autenrieth DM, Baumgart DC. Toxic megacolon. Inflamm Bowel Dis 2012;18:584-91.
79           Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012;380:1590-605.
80           Buning C, Geissler N, Prager M, Sturm A, Baumgart DC, Buttner J, Buhner S, Haas V, Lochs H. Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? Inflamm Bowel Dis 2012;18:1932-9.
81           Louis E, Baumgart DC, Ghosh S, Gomollon F, Hanauer S, Hart A, Irving P. What changes in inflammatory bowel disease management can be implemented today? J Crohns Colitis 2012;6 Suppl 2:S260-7.
82           Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-19.
83           Pohl H, Tanczos BT, Rudolph B, Meining A, Khalifa AC, Rosch T, Baumgart DC. Probe-based confocal laser microscopy identifies criteria predictive of active celiac sprue. Dig Dis Sci 2012;57:451-7.
84           Prager M, Buttner J, Haas V, Baumgart DC, Sturm A, Zeitz M, Buning C. The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action. Int J Colorectal Dis 2012;27:565-73.
85           Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P, Retic Study G. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012;142:473-81 e4.
86           Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 2012;20:1-18.
87           Baumgart DC, Sandborn WJ. Erratum: Crohn's disease (The Lancet (2012) 380 (1590-605)). The Lancet 2013;381:204.
88           Fischer A, Gluth M, Pape UF, Wiedenmann B, Theuring F, Baumgart DC. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-alpha on tight junction proteins and signaling pathways in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2013;304:G970-9.
89           Kohnke T, Gomolka B, Bilal S, Zhou X, Sun Y, Rothe M, Baumgart DC, Weylandt KH. Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators. Biomed Res Int 2013;2013:748160.
90           Muller T, Beutler C, Pico AH, Otten M, Durr A, Al-Abadi H, Guckelberger O, Meyer Zum Buschenfelde D, Johrens K, Volkmann M, Lankisch T, Voigtlander T, Anders M, Shibolet O, Jefferson DM, Podolsky DK, Fischer A, Veltzke-Schlieker W, Adler A, Baumgart DC, Sturm A, Wiedenmann B, Schott E, Berg T. Increased T-helper 2 cytokines in bile from patients with IgG4-related cholangitis disrupt the tight junction-associated biliary epithelial cell barrier. Gastroenterology 2013;144:1116-28.
91           Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, Danese S, Halligan S, Marincek B, Matos C, Peyrin-Biroulet L, Rimola J, Rogler G, van Assche G, Ardizzone S, Ba-Ssalamah A, Bali MA, Bellini D, Biancone L, Castiglione F, Ehehalt R, Grassi R, Kucharzik T, Maccioni F, Maconi G, Magro F, Martin-Comin J, Morana G, Pendse D, Sebastian S, Signore A, Tolan D, Tielbeek JA, Weishaupt D, Wiarda B, Laghi A. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 2013;7:556-85.
92           Pohl H, Wrobel K, Bojarski C, Voderholzer W, Sonnenberg A, Rosch T, Baumgart DC. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol 2013;108:200-7.
93           Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B, Schreiber S, Mansfield JC, Williams M, Tang M, Visich J, Wei X, Keir M, Luca D, Danilenko D, Egen J, O'Byrne S. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 2013;62:1122-30.
94           Fischer A, Gluth M, Weege F, Pape UF, Wiedenmann B, Baumgart DC, Theuring F. Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1. Am J Physiol Gastrointest Liver Physiol 2014;306:G218-28.
95           Gerlach UA, Vrakas G, Reddy S, Baumgart DC, Neuhaus P, Friend PJ, Pascher A, Vaidya A. Chronic intestinal failure after Crohn disease: when to perform transplantation. JAMA Surg 2014;149:1060-6.
96           Papanikolaou IS, van der Voort IR, Chopra SS, Seebauer CJ, Rump J, Papas MG, Triantafyllou K, Baumgart DC, Teichgraber UK, Wiedenmann B, Rosch T. MRI-guided percutaneous transhepatic cholangiodrainage: feasibility study in a porcine model. Scand J Gastroenterol 2014;49:722-6.
97           Prager M, Durmus T, Buttner J, Molnar T, de Jong DJ, Drenth JP, Baumgart DC, Sturm A, Farkas K, Witt H, Buning C. Myosin IXb variants and their pivotal role in maintaining the intestinal barrier: a study in Crohn's disease. Scand J Gastroenterol 2014;49:1191-200.
98           Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014;384:309-18.
99           Baumgart DC. [The human microbiome]. Dtsch Med Wochenschr 2015;140:1451-6.
100         Baumgart DC, Muller HP, Grittner U, Metzke D, Fischer A, Guckelberger O, Pascher A, Sack I, Vieth M, Rudolph B. US-based Real-time Elastography for the Detection of Fibrotic Gut Tissue in Patients with Stricturing Crohn Disease. Radiology 2015;275:889-99.
101         Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Buning C, Howaldt S, Stallmach A, Group AS. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis 2015;21:579-88.
102         Krupka N, Baumgart DC. Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab. Drug Des Devel Ther 2015;9:147-54.
103         Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S, Vedolizumab Germany C. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016;43:1090-102.
104         Baumgart DC, le Claire M. The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds. PLoS One 2016;11:e0147364.
105         Baumgart DC, Wende I, Grittner U. Tablet computer-based multimedia enhanced medical training improves performance in gastroenterology and endoscopy board style exam compared with traditional medical education. Gut 2016;65:535-6.
106         Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis 2016;10:812-20.
107         Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S, Collaborators ACSG. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet 2016;388:1281-90.
108         Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P, Group PS. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology 2016;150:1568-78.
109         Roggenbuck D, Reinhold D, Baumgart DC, Schierack P, Conrad K, Laass MW. Autoimmunity in Crohn's Disease-A Putative Stratification Factor of the Clinical Phenotype. Adv Clin Chem 2016;77:77-101.
110         Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Buning C, Group AS. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. Aliment Pharmacol Ther 2016;44:259-70.
111         Schmidt KJ, Muller N, Dignass A, Baumgart DC, Lehnert H, Stange EF, Herrlinger KR, Fellermann K, Buning J. Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues. J Crohns Colitis 2016;10:31-7.
112         Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Aliment Pharmacol Ther 2016;44:1199-212.
113         Teich N, Mohl W, Bokemeyer B, Bundgens B, Buning J, Miehlke S, Huppe D, Maaser C, Klugmann T, Kruis W, Siegmund B, Helwig U, Weismuller J, Drabik A, Stallmach A, German IBDSG. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity. J Crohns Colitis 2016;10:61-8.
114         Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME. Association Between Response to Etrolizumab and Expression of Integrin alphaE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology 2016;150:477-87 e9.
115         Autenrieth DM, Baumgart DC. [Microbiome and Gut Inflammation]. Dtsch Med Wochenschr 2017;142:261-6.
116         Baumgart DC, Wende I, Grittner U. Tablet computer enhanced training improves internal medicine exam performance. PLoS One 2017;12:e0172827.
117         Julsgaard M, Kjeldsen J, Baumgart DC. Vedolizumab safety in pregnancy and newborn outcomes. Gut 2017.
118         Kucharzik T, Wittig BM, Helwig U, Borner N, Rossler A, Rath S, Maaser C, group Ts. Use of Intestinal Ultrasound to Monitor Crohn's Disease Activity. Clin Gastroenterol Hepatol 2017;15:535-42 e2.
119         Steinhagen PR, Baumgart DC. [Fundamentals of the microbiome]. Internist (Berl) 2017;58:429-34.
120         Mogl M, Baumgart DC, Fischer A, Pratschke J, Pascher A. Immunosuppression following liver transplantation and the course of inflammatory bowel disease – a case control study. Z Gastroenterol. 2017 Dec 6. doi: 10.1055/s-0043-117183. [Epub ahead of print]
121         D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O. Central nervous system immune surveillance and circulating Β7+CD4 T cells under anti-MAdCAM-1 antibody treatment for Crohn's disease: report of the TOSCA studyEffect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating beta7+ T Cells in Crohn's Disease: Report of the TOSCA Study. J Crohns Colitis. 2017 Sep 16. doi: 10.1093/ecco-jcc/jjx128. [Epub ahead of print].
122.        Julsgaard M, Kjeldsen J, Bibby BM, Brock B, Baumgart DC. Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.Gastroenterology. 2017 Oct 5. pii: S0016-5085(17)36132-2. doi: 10.1053/j.gastro.2017.08.067. [Epub ahead of print]

Books and Chapters

Medical English

P Gross, DC Baumgart. Medical English. Thieme, Stuttgart-New York, 3rd ed., 2002.

Medical English

P Gross,DC Baumgart. Medical English. Thieme, Stuttgart-New York, 4th ed., 2003.

Medical English

P Gross,DC Baumgart. Medical English. Thieme, Stuttgart-New York, 5th ed., 2006.

Medical English Japanese Edition

P Gross,DC Baumgart. Medical English. Ohmsha Publishers, Tokyo, 1st Japanese ed., 2007.

Anglais Médical

P. Gross, DC Baumgart. Medical English (Anglais médical). Paris, Vigot-Maloine Publishers, 1st French ed., 2008

Anglais Médical

P. Gross, DC Baumgart. Medical English (Anglais médical). Paris, Vigot-Maloine Publishers, 2. French ed., 2009

Harrison's

DC Baumgart, B Wiedenmann. German Edition: Harrison' Principles of Internal Medicine, 15th ed., 2002.
Chapter 33: Dysphagia
Chapter 34: Nausea, Vomiting and Indigestion
Chapter 35: Diarrhea and Constipation
Chapter 36: Weight Loss
Chapter 37: Gastrointestinal Bleeding
Chapter 38: Jaundice
Chapter 39: Abdominal Swelling and Ascites
Chapter 93: Endocrine Tumors of the Gastrointestinal Tract and the Pancreas

Harrison's

DC Baumgart, B Wiedenmann. German Edition: Harrison' Principles of Internal Medicine, 16th ed.,, 2005.
Chapter 33: Dysphagia
Chapter 34: Nausea, Vomiting and Indigestion
Chapter 35: Diarrhea and Constipation
Chapter 36: Weight Loss
Chapter 37: Gastrointestinal Bleeding
Chapter 38: Jaundice
Chapter 39: Abdominal Swelling and Ascites
Chapter 93: Endocrine Tumors of the Gastrointestinal Tract and the Pancreas

Harrisons's

DC Baumgart und B Wiedenmann. German Edition.: Harrison' Principles of Internal Medicine, 17th ed., 2008.
Chapter 38: Dysphagia
Chapter 39: Nausea, Vomiting and Indigestion
Chapter 40: Diarrhea and Constipation
Chapter 41: Weight Loss
Chapter 42: Gastrointestinal Bleeding
Chapter 43: Jaundice
Chapter 44: Abdominal Swelling and Ascites
Chapter 344: Endocrine Tumors of the Gastrointestinal Tract and the Pancreas

Biologische Therapie

DC Baumgart, AU Dignass. Etiopathogenesis, Genetics and Environmental Factors. In: Biologic Therapy of Inflammatory Bowel Disease. Ed. AU Dignass, Uni-Med Science Publishers, Bremen-Boston, 1st ed., 2004: 18-41.

Biologische Therapie

DC Baumgart, AU Dignass. Mechanisms of Biologic Therapies. In: Biologic Therapy of Inflammatory Bowel Disease. Ed. AU Dignass, Uni-Med Science Publishers, Bremen-Boston, 1st ed., 2004: 18-41.

Biologische Therapie

DC Baumgart, H Schulze, AU Dignass. Biologische Therapie der chronisch entzündlichen Darmerkrankungen. Ed. AU Dignass, Uni-Med Science Publishers, Bremen-Boston, 2. Auflage, 2010.

Biolologic Therapy

DC Baumgart. Biologic Therapy for Inflammatory Bowel Diseases. Uni-Med Science Publishers, Bremen-Boston, 1st. ed. 2010.

Controversies in IBD

DC Baumgart. Refractory ulcerative colitis: is surgery always indicated? In: Trends and Controversies in IBD: Evidence-Based Approach or Individual Management? In: Trends and Controversies in Inflammatory Bowel Disease. Eds. Dignass AU, Lochs H, Stange EF. Springer Netherland, 1st ed., 2004.

Enddarm

DC Baumgart, B Wiedenmann. Gastroenterology and Hepatology: Diseases of the Colon and Rectum. In: Internal Medicine - essentials. Eds.. Lehnert H, Werdan K. Thieme, Stuttgart, 4th ed., 2005: 205-214.

Novel Therapies in IBD

DC Baumgart. Novel Therapies in IBD: T-cell modulating antibodies. In: Immunoregulation in Inflammatory Bowel Diseases - Current Understanding and Innovation. Eds. Dignass A, Rachmilewitz D, Stange EF, Weinstock JV. Springer, Berlin-New York, 1st ed., 2007: 194-201.

Innere Medizin

DC Baumgart, B Wiedenmann. Short bowel syndrome and small bowel transplantation. In: Internal Medicine. Eds. Classen M, Diehl V, Kochsiek K, Böhm B, Schmiegel W. Elsevier, Munich, 6th ed., 2009.

Praktische Gastroenterologie

DC Baumgart. Small bowel transplantation. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers. 3rd ed. 2008.

Praktische Gastroenterologie

Keller J, DC Baumgart. Short bowel syndrome. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers, 3rd ed., 2008.

Praktische Gastroenterologie

DC Baumgart, Rosien U. Gastroenterological complications following hematopoietic stem cell transplantation. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers, 4th ed. 2011.

Praktische Gastroenterologie

DC Baumgart. Small bowel transplantation. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers. 4th ed. 2011.

Praktische Gastroenterologie

Keller J, DC Baumgart. Short bowel syndrome. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers, 4th ed., 2011.

Praktische Gastroenterologie

DC Baumgart, Rosien U. Gastroenterological complications following hematopoietic stem cell transplantation. In: Practical Gastroenterology. Eds. Layer P, Rosien U. Urban & Fischer Publishers, 4th ed. 2011

Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach

DC Baumgart. Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. Springer, New York, 1st ed. 2012

Fischer A, Baumgart DC. Tacrolimus, Sirolimus and Mycophenolate Mofetil. In: Medical Therapy of Ulcerative Colitis. Ed. Lichtenstein G. Springer New York 1. Auflage 2015